Company: TVRD
Filing Date: 2025-11-13
Form Type: 424B3
Source: 0001104659-25-111336
Chunk: 60

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 424B3
Chunk 60
---
 492 |   | $      |   520 |   |   105.7 | % |                 $ | 2,659 |   |    $ | 1,501 |   | $      | 1,158 |   |    77.1 | % |
| Professional fees                         | ​ |                  ​ | 1,001 | ​ |    ​ | 269 | ​ | ​      |   732 |   |   272.1 | % |                 ​ | 3,131 | ​ |    ​ |   410 | ​ | ​      | 2,721 |   |   663.7 | % |
| Insurance costs                           | ​ |                    |   177 | ​ |      |  16 | ​ |        |   161 |   | 1,006.3 | % |                   |   342 | ​ |      |    46 | ​ |        |   296 |   |   643.5 | % |
| Rent and other costs                      | ​ |                    |   145 | ​ |      | 104 | ​ |        |    41 |   |    39.4 | % |                   |   509 | ​ |      |   301 | ​ |        |   208 |   |    69.1 | % |
| Total general and administrative expenses | ​ |                  $ | 2,335 | ​ |    $ | 881 | ​ | $      | 1,454 |   |   165.0 | % |                 $ | 6,641 | ​ |    $ | 2,258 | ​ | $      | 4,383 |   |   194.1 | % |

​

General and administrative expenses were $2.3 million
for the three months ended September 30, 2025, compared to $0.9 million for the three months ended September 30, 2024.
The increase of approximately $1.5 million was primarily driven by increases in professional fees of $0.7 million, attributable to increased
legal fees and ongoing accounting and audit fees. The remaining increase was attributable to increases in personnel costs, insurance costs,
and rent and other related costs.

General and administrative expenses were $6.6 million
for the nine months ended September 30, 2025, compared to $2.3 million for the nine months ended September 30, 2024